What Is Retatrutide?
Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple mechanism distinguishes it from dual-agonist peptides like tirzepatide (GLP-1/GIP) and single-agonist compounds like semaglutide (GLP-1 only), making it the most broadly acting incretin-class compound currently under clinical investigation.
The addition of the glucagon receptor — absent from all other approved or late-stage metabolic peptides — activates energy expenditure pathways that the GLP-1 and GIP receptors alone do not reach. This is believed to explain the unprecedented magnitude of weight reduction observed in Phase 2 clinical trials. For a full overview of retatrutide’s mechanism and receptor pharmacology, see our Retatrutide Triple-Agonist Research Guide.
Retatrutide Dosage in Clinical Trials
The primary source of dosage data for retatrutide comes from the Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023). This 48-week, randomized, double-blind, placebo-controlled study enrolled 338 adults with obesity or overweight with at least one weight-related comorbidity.
The trial evaluated multiple dosing cohorts with an escalation schedule designed to minimize gastrointestinal side effects during the initial weeks of treatment:
| Cohort | Starting Dose | Escalation | Maintenance Dose | Weight Loss at 48 Weeks |
|---|---|---|---|---|
| 1mg | 1mg weekly | No escalation | 1mg weekly | -8.7% |
| 4mg (escalated) | 2mg weekly | Increased to 4mg at week 4 | 4mg weekly | -17.1% |
| 4mg (no escalation) | 4mg weekly | No escalation | 4mg weekly | -15.7% |
| 8mg (escalated) | 2mg weekly | +2mg every 4 weeks | 8mg weekly | -22.1% |
| 12mg (escalated) | 2mg weekly | +2mg every 4 weeks | 12mg weekly | -24.2% |
Key Observations From Dosage Data
Dose-dependent response
Weight reduction increased in a clear dose-dependent pattern across all cohorts. The 12mg cohort achieved the highest mean body weight reduction at -24.2% — exceeding all published results for semaglutide (approximately -16% in the STEP trials) and tirzepatide (approximately -22.5% in SURMOUNT-1) at their respective maximum doses. Notably, participants in the 12mg group had not reached a weight loss plateau at 48 weeks, suggesting that longer treatment durations could yield even greater reductions.
Escalation reduces side effects
The comparison between the 4mg escalated and 4mg non-escalated cohorts provides critical insight into dosing strategy. Both groups reached the same maintenance dose, but the escalated group achieved greater weight loss (-17.1% vs -15.7%) with fewer gastrointestinal adverse events. This established dose escalation as the standard approach for retatrutide — starting low and increasing gradually allows the body to adapt to GLP-1 and glucagon receptor activation.
Frequency of administration
All clinical trial cohorts used once-weekly subcutaneous injection. Retatrutide’s pharmacokinetic profile supports a 7-day dosing interval, with steady-state plasma concentrations achieved after approximately 4-5 weeks of consistent dosing. The half-life is approximately 6 days.
Dose Escalation Schedule
Based on the Phase 2 trial protocol, the escalation schedule for the 12mg maintenance cohort:
| Period | Weekly Dose | Duration |
|---|---|---|
| Initiation | 2mg | Weeks 1-4 |
| Escalation 1 | 4mg | Weeks 5-8 |
| Escalation 2 | 6mg | Weeks 9-12 |
| Escalation 3 | 8mg | Weeks 13-16 |
| Escalation 4 | 10mg | Weeks 17-20 |
| Maintenance | 12mg | Week 21 onward |
How Retatrutide Dosing Compares to Other GLP-1 Peptides
| Compound | Receptors | Max Dose | Frequency | Max Weight Loss |
|---|---|---|---|---|
| Retatrutide | GLP-1 + GIP + Glucagon | 12mg | Weekly | -24.2% (48 wk) |
| Tirzepatide | GLP-1 + GIP | 15mg | Weekly | -22.5% (72 wk) |
| Semaglutide | GLP-1 | 2.4mg | Weekly | -16.0% (68 wk) |
For a detailed head-to-head analysis, see our Semaglutide vs Retatrutide vs Tirzepatide Comparison.
Reconstitution and Preparation
Research-grade retatrutide is supplied as lyophilized powder that must be reconstituted with bacteriostatic water before use. Common reconstitution volumes for PSPeptides retatrutide vials:
| Vial Size | BAC Water | Concentration |
|---|---|---|
| Retatrutide 5mg | 2.5mL | 2mg/mL |
| Retatrutide 10mg | 2.5mL | 4mg/mL |
| Retatrutide 20mg | 4.0mL | 5mg/mL |
| Retatrutide 30mg | 5.0mL | 6mg/mL |
For step-by-step instructions, see our How to Reconstitute Peptides Guide. To calculate exact volumes, use our free Peptide Reconstitution Calculator.
Reported Side Effects by Dose Level
| Side Effect | 1mg | 4mg | 8mg | 12mg |
|---|---|---|---|---|
| Nausea | 6% | 22-25% | 29% | 31% |
| Diarrhea | 6% | 16-22% | 22% | 25% |
| Vomiting | 0% | 6-13% | 13% | 16% |
| Decreased appetite | 3% | 9-13% | 16% | 19% |
Most gastrointestinal side effects were mild to moderate and occurred primarily during dose escalation. Frequency generally decreased as participants remained on a stable dose.
Frequently Asked Questions
What is the most effective retatrutide dose based on clinical data?
The 12mg weekly maintenance dose produced the greatest weight reduction (-24.2%) in Phase 2 trials. However, the 4mg dose produced clinically significant results (-17.1%), and the 8mg dose achieved -22.1%. The optimal dose depends on the balance between efficacy and tolerability.
How long does it take to reach the full maintenance dose?
Using the clinical trial escalation protocol (2mg increases every 4 weeks), reaching the 12mg maintenance dose takes approximately 20 weeks.
Is retatrutide administered daily or weekly?
Weekly. All clinical trial protocols used once-weekly subcutaneous injection. The compound’s approximately 6-day half-life supports this dosing frequency.
How does retatrutide dosing compare to semaglutide?
Semaglutide’s maximum approved dose for weight management is 2.4mg weekly. Retatrutide’s maximum studied dose is 12mg weekly. These are different molecules with different potencies — direct mg-to-mg comparisons are not meaningful. Retatrutide at 12mg produced greater weight reduction than semaglutide at 2.4mg in separate trials.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022;34(9):1234-1247.e9.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544.
Buy Research-Grade Retatrutide — From $39.99 → | Buy BAC Water →
This content is for educational and research purposes only. All products are intended for laboratory research use only. Not for human consumption.